JointHealth™ express   November 22, 2006

Health Canada has approved adalimumab (Humira®) for use in the treatment of ankylosing spondylitis. Adalimumab (Humira®) was issued its Notice of Compliance (NOC) on October 17, 2006.

This is great news for Canadians living with active ankylosing spondylitis (AS).

This medication is a biologic response modifier targeting the TNF-alpha molecule, also known as a TNF-blocker. TNF-blockers can be effective at reducing arthritis in the spine as well as peripheral joints. Adalimumab will be used to treat people with ankylosing spondylitis who do not respond sufficiently to the current standard of care, namely, non-steroidal anti-inflammatories such as ibuprofen (Advil®).

There are now three TNF-blockers approved for use in the treatment of ankylosing spondylitis in Canada. Each of the three works in the body a different way, and there is no way to predict which one may work in a given person.

To learn if adalimumab or another ankylosing spondylitis treatment may be helpful to you, please speak to your rheumatologist or other health care provider helping you to manage your disease.

To view the Notice of Compliance, please visit and search for "Humira".